Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/velpatasvir with or without ribavirin in chronic genotype 3 hepatitis C with cirrhosis
2016-000417-73Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- May 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in chronic hepatitis C (CHC) comparing Sofosbuvir/velpatasvir with Sofosbuvir/velpatasvir + ribavirin (2 arms). Primary endpoint: SVR12. Started May 2016; status: completed.
02
Drugs
sofosbuvirvelpatasvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2016-000417-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000417-73.